Aktis Oncology, Inc. (AKTS)

Aktis Oncology Statistics

Total Valuation

Aktis Oncology has a market cap or net worth of $988.89 million. The enterprise value is $773.65 million.

Market Cap	988.89M
Enterprise Value	773.65M

Important Dates

The next estimated earnings date is Tuesday, May 12, 2026, before market open.

Earnings Date	May 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Aktis Oncology has 55.28 million shares outstanding.

Current Share Class	53.40M
Shares Outstanding	55.28M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.42%
Owned by Institutions (%)	5.71%
Float	23.64M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	152.21
Forward PS	117.51
PB Ratio	5.28
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	119.08
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.37, with a Debt / Equity ratio of 0.06.

Current Ratio	7.37
Quick Ratio	7.26
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -29.45% and return on invested capital (ROIC) is -20.45%.

Return on Equity (ROE)	-29.45%
Return on Assets (ROA)	-15.79%
Return on Invested Capital (ROIC)	-20.45%
Return on Capital Employed (ROCE)	-31.96%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	$85,487
Profits Per Employee	-$838,566
Employee Count	76
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	19.21
200-Day Moving Average	n/a
Relative Strength Index (RSI)	46.97
Average Volume (20 Days)	480,170

Short Selling Information

The latest short interest is 1.17 million, so 2.11% of the outstanding shares have been sold short.

Short Interest	1.17M
Short Previous Month	1.00M
Short % of Shares Out	2.11%
Short % of Float	4.93%
Short Ratio (days to cover)	6.02

Income Statement

In the last 12 months, Aktis Oncology had revenue of $6.50 million and -$63.73 million in losses.

Revenue	6.50M
Gross Profit	6.50M
Operating Income	-74.68M
Pretax Income	-63.73M
Net Income	-63.73M
EBITDA	-72.36M
EBIT	-74.68M
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has $226.79 million in cash and $11.55 million in debt, with a net cash position of $215.24 million or $3.89 per share.

Cash & Cash Equivalents	226.79M
Total Debt	11.55M
Net Cash	215.24M
Net Cash Per Share	$3.89
Equity (Book Value)	187.26M
Book Value Per Share	n/a
Working Capital	199.07M

Cash Flow

In the last 12 months, operating cash flow was -$64.13 million and capital expenditures -$9.58 million, giving a free cash flow of -$73.71 million.

Operating Cash Flow	-64.13M
Capital Expenditures	-9.58M
Depreciation & Amortization	2.33M
Net Borrowing	n/a
Free Cash Flow	-73.71M
FCF Per Share	-$1.33

Margins

Gross Margin	100.00%
Operating Margin	-1,149.52%
Pretax Margin	-980.93%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Aktis Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-6.44%
FCF Yield	-7.45%

Analyst Forecast

The average price target for Aktis Oncology is $31.50, which is 76.08% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$31.50
Price Target Difference	76.08%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a